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INTRODUCTION
A major toxicity of total body irradiation (TBI) used in
the preparation of patients for bone marrow transplantation
is radiation pneumonitis [1–13]. Ionizing irradiation-
induced lung damage has been shown to directly correlate
with total dose [1], fraction size [12], and volume of lung
irradiated [10]. In TBI patients, several strategies to decrease
radiation pneumonitis have been attempted. These have includ-
ed: decreasing the total dose with dose-rates from around
5 cGy/minute up to as high as 30 cGy/minute [10,15]; fraction-
ating TBI with one or two fractions of around 125 cGy/day
over 3 or 4 days [10,16–20]; and adding techniques of lung
blocking either by using full thickness blocks on the second or
third day of a 4-day treatment regimen or, alternatively, using a
50% transmission block for the entire 4 days of a fractionated
program [10–11,19]. The techniques of lung and liver
blocking have decreased pulmonary toxicity but result in a
higher recurrence rate [8].
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ABSTRACT
Radiation pneumonitis remains a critical dose-limiting toxicity of total body irradiation (TBI) for use in bone marrow
transplantation. The acute and chronic phases of radiation damage in the mouse lung have been shown to correlate
with mouse strain genotype and are dependent on fraction size, total dose, and total lung volume. Our prior studies
demonstrated effective prevention of irradiation-induced lung damage and improved survival in C57BL/6J mice by
MnSOD plasmid/liposome gene therapy. In the present studies, we investigated the kinetics of irradiation-induced
upregulation of mRNA for acute phase cytokines interleukin (IL)-1 and tumor necrosis factor (TNF)-a, and fibrosis-
associated transforming growth factor (TGF)-ß and isoforms (TGF-b1, TGF-b2 and TGF-b3) in 2000 cGy whole-
lung irradiated C57BL/6J mice, a strain known to develop dose and volume-dependent organizing alveolitis/fibrosis.
The results demonstrate increase in mRNA for IL-1 between days 1 and 14 after irradiation with return to baseline
levels out to 120 days. TNF-a mRNA levels were not initially elevated but increased between 80 and 100 days and
then decreased by 120 days. The mRNA levels for TGF-b1 demonstrated an initial increase within the first 14 days
after total lung irradiation with a decrease to baseline levels out to 100 days. Then, in striking contrast to the other
two cytokines, an increase in TGF-b2 mRNA occurred at around 120 days and correlated with the detection of orga-
nizing alveolitis/radiation fibrosis and mortality. These results are consistent with a two-phase mechanism in the
molecular pathology of irradiation lung injury, in which IL-1 cytokine mRNA levels correlated with the acute pneu-
monitis phase and delayed elevation of TNF-a (80–100 days), TGF-b1 (100 days), and TGF-b2 (120 days) were associ-
ated with the fibrosis phase. Insight into the cell-specific and tissue-specific molecular mechanisms of ionizing irradia-
tion induction of mRNA for pulmonary cytokines may provide new strategies for treatment of radiation pneumonitis
in TBI patients.
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Pulmonary toxicity has been one motivation for new
marrow transplant programs to clinically test alternative
forms of patient preparation for marrow transplant that
avoid irradiation, including the use of busulfan/cyclophos-
phamide or other chemotherapy regimens in the absence of
TBI [21–24]. Limited success in using these alternatives in
curing patients with acute myeloid leukemia in second or
third remission [17, 24–25], T-cell leukemia [26], chronic
myelogenous leukemia [18], multiple myeloma [27], or
other disease categories in which TBI is utilized [27–28]
suggest that this modality will have continued widespread
appeal for use in new clinical protocols.
The mechanism of ionizing irradiation-induced lung
injury is poorly understood, but has been shown to correlate
with increased plasma levels of TGF-b [29] and other
cytokines [29] associated with other forms of infectious or
toxic tissue injury. The acute pathologic phase of irradiation
lung injury includes detectable alveolar transudate and
endothelial cell swelling [30]. A subacute phase includes
inflammatory cell infiltrate and suggests some elements of
common pathophysiology with pulmonary injury from
hyperbaric oxygen or inhaled toxic chemicals [30–31].
Rodent models of radiation pneumonitis have been
particularly helpful in elucidating the regulatory controls over
both the acute and chronic phases of lung injury [30–34].
Several strains of mice have been demonstrated to develop a
predictable pattern of organizing alveolitis/fibrosis, including
the C57BL/6J mouse [31,33], while other strains appear
resistant to this form of lung injury, including the C3H/HeJ
mouse [29,34]. In back cross and F2 generation experiments,
several genetic loci have been shown to be involved in the
mechanism of susceptibility to radiation- induced organizing
alveolitis [31,33–35]. Whether the critical irradiation tissue
injury is sustained by alveolar type-two cells and tracheo-
bronchial cells, bronchial endothelial cells, alveolar macro-
phages, or several cell types is not yet known [30,33,35].
Recent evidence suggests that levels of vascular endothelial
growth factor increase after total lung irradiation in the
C57BL/6J mouse [34]. These data point to initial injury in
endothelial cells as perhaps critical to the cascade of events
leading to radiation pneumonitis and subsequent radiation
fibrosis. 
Pharmacologic methods of radiation protection, including
inhalation of acetylcysteine (Mucomyst) and other radical
scavenger compounds, have been tested with limited success
[36]. The use of inhaled antioxidant enzymes or radioprotective
drugs has also been of limited success [37]. We have recently
demonstrated the effectiveness of a method of radioprotective
gene therapy using plasmid/liposome or adenovirus delivery of
the manganese superoxide dismutase (MnSOD) transgene to
the lungs of C57BL/6J mice [38–40]. These data show protection
from acute radiation-induced cytokine increases, and a
decrease in the appearance of organizing alveolitis/fibrosis and
death at 150 days. The mechanism of pulmonary irradiation
late effects and its correlation with acute effects is the subject
of controversy. Corticosteroid treatment has been demonstrated
to significantly decrease acute irradiation damage in the rat
lung with minimal effect on late induction of fibrosis [41].
These data suggest a separate mechanism for the late effect of
irradiation lung damage. In other models of radiation protection,
intratracheal injection of basic fibroblast growth factor has
been shown to decrease the initial, but not late, irradiation
damage to the mouse lung [42].
Our prior studies did not address the events occurring in
the lung between the acute and late injury. In the present
study, we correlated the time course of appearance of organizing
alveolitis in the mouse lung with levels of cytokine mRNA in
total lung extracts at each of several intermediate time
points. The experiments were carried out to determine
whether the pathologic changes in the lung, which are
predictably detected between 120 and 150 days in C57BL/6J
mice after irradiation, correlated with the earlier appearance
of a specific cytokine mRNA. If such a result were obtained
and could point toward the appearance of a late irradiation
injury, perhaps caused by apoptosis of a slowly proliferating
cell population in the pulmonary parenchyma or vasculature,
new interventional strategies might be designed. The results
demonstrate a complex pattern of elevation of cytokine
mRNA levels following total lung irradiation but with a clear
indication that a late increase in the levels of two specific
isoforms of TGF- b1 and TGF- b2 is reproducibly detected.
MATERIALS AND METHODS
Mice intratracheal liposome injections and irradiation
C57BL/6J female mice (30–33 gm) (Jackson Laboratories,
Bar Harbor, ME) were intratracheally injected with 78 mL
of either MnSOD plasmid liposome complex or LacZ
plasmid/liposome complex. Mice were anesthetized with
1.25 mg of nembutal anesthesia/20 mg body weight (Abbott
Laboratories, North Chicago, IL) as an intraperitoneal
injection. The trachea was surgically exposed and a 1 cc
syringe with a 28-gauge needle was used to inject into the
trachea. The incision was closed with Autoclip 9.0 mm
wound clips (Clay Adams, Parsippany, NJ). The pRK5 plasmid
containing the human MnSOD cDNA as a transgene [43]
and pIEP-LacZ plasmid [44] were grown in Luria-Bertani
medium and isolated using Qiagen Giga columns (Qiagen,
Chatsworth, CA). The plasmid DNA was resuspended in
nuclease-free water at a concentration of 10 mg/ml. For each
mouse to be injected, 500 mg of DNA (50 mL) and 28 mL of
Lipofectin (Gibco/BRL, Grand Island, NY) were mixed and
allowed to sit at room temperature for 30 minutes. The com-
plexes were then placed on ice until the time of injection.
Groups of 200 C57BL/6J mice received 2000 cGy to the
pulmonary cavity one day after plasmid/liposome injection.
All mice received single fraction irradiation to both lungs
delivered by a 6 MeV linear accelerator Varian, dose rate 200
cGy/min at the mid-thoracic plane [38–39].The head and
abdomen were shielded by ten 1/2 value layer lead blocks.
Slot blots
For slot blots, 10 mg of total RNA was dissolved in 100
mL of diethyl pyrocarbonate (DEPC) (Sigma Chemical
Company, St. Louis, MO) treated H2O, followed by addition
of 300 mL of a solution of 6.15M formaldehyde and 103
SSC. The RNA was incubated at 678C for 15 minutes and
loaded onto a Schleicher & Schuell Minifold II slot blot system
(Schleicher & Schuell, Keene, NH), where the RNA is bound
to BA85 nitrocellulose membrane (Schleicher & Schuell).
The membrane was baked for 2 hours at 428C, prehybridized
in Denhardt’s buffer (50% formamide, 53 Denhardt’s
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reagent, 100 mg/mL denatured salmon sperm DNA, 0.1%
SDS, and 53 SSPE). The membrane was probed for 18
hours at 428C with a p32-labeled PCR fragment of the
MnSOD gene, then was washed twice in 13 SSPE/0.1%
SDS for 5 minutes at room temperature followed by two
washes in 0.13 SSPE/0.1% SDS at 428C for 30 minutes. The
blots were placed in an autoradiographic cassette with X-ray
film. Densitometric analysis was carried out to determine the
binding of the probe to the blot using a Molecular Dynamics
Personal Densitometer SI (Molecular Dynamics, Sunnyvale,
CA). The membrane was stripped of radioactivity by placing
the blot in 0.13 SSPE/0.1% SDS that had been heated to
1008C. After cooling to 65–708C, the membrane was prehy-
bridized as described above and reprobed for IL-1, TNF-a,
TGF-b1, TGF-b2 and TGF-b3 with actin or glyceralde-
hyde-3-phosphate dehydrogenase (G3PDH) (Clontech
Laboratories, Palo Alto, CA) as standards. The cDNA probes
for TGF-b1 (0.9 kb), TGF-b2 (1.0 kb) and TGF-b3 (0.75
kb) were a gift from Dr. Sonia B. Jakowlew of the Biomarkers
and Prevention Research Division, National Cancer Institute
and National Institutes of Health, Bethesda, MD. Densitometry
was carried out as published and all results normalized
separately using primer sets for actin and G3PDH. 
Histopathology
For each treatment group, 5–10 mice were killed at
each time point for both the slot blot analysis of cytokines
and histopathological examination for irradiation-induced
lung damage. The lungs were expanded by intratracheal
injection of 0.8 mL of Optimum Cutting Temperature
(OCT) compound, (Sakura Fine Tek, Torrance, CA) fol-
lowed by excision. The five lobes of each mouse lung were
separated, placed in each of five 15 3 15 mm base molds,
and frozen in OCT [45]. Nine sections (each 10 microns
thick) were prepared from each lobe with 100 microns
between each section using a Shandon AS620E Cryotome
(Shandon/Lipshaw, Pittsburgh, PA). The sections were
hematoxylin and eosin (H&E)-stained as described [38].
The slides were dehydrated, mounted with Permamount
(Fisher Scientific, Pittsburgh, PA), then visually scored for
the percent of the lung exhibiting fibrosis and/or alveolitis
[31]. For each mouse, at least seven sections were prepared
from each of five lobes and scored separately. At least 36
total sections were analyzed by an Optimus Image Analysis
System (Bothwell, WA) to quantitate the percent of lung
involved with organizing alveolitis for each mouse. The
method is to project the entire section on a computer moni-
tor screen. Then with a hand-held pendant, each area of
organizing alveolitis is traced and the area of each involved
section is circled. The software algorithm calculates the
percent of the total lung section surface area that is
accounted for in the circled area, and this percent then is
the percent alveolitis for that section. The automated scor-
ing closely correlated with visual manual scoring from prior
studies [38,40]. Irradiation-induced organizing alveolitis, the
late histologic changes detected in C57BL/6J mice, were
scored from H&E-stained sections [31]. The methods for
collagen histochemical stains have been published previous-
ly and are shown in prior studies to correlate with percent
organizing alveolitis detected by H&E stains in this strain
[31].
Statistics
Standard survival analysis included Kaplan-Meier plots
of survivor function and log rank tests of differences
between treatment groups [46,47]. Prognostic factors,
including radiation dose and radiation protection methods
among genetically similar mice, were examined with Cox
regression [48]. The association between alveolitis rates and
survival was examined by adding mouse median alveolitis
(fibrosis) rates as time-dependent covariates. Treatment
group differences in alveolitis were tested by nonparametric
methods; either the Wilcoxon test for two samples of the
Kruskal-Wallis test, or the Jonckheere-Terpstra method for
overall differences or trends [49–50] The group differences
were applied to mouse median percent alveolitis.
Animal welfare
All protocols were approved by the Institutional Animal
Care and Use Committee of the University of Pittsburgh.
Veterinary care was provided by the Central Animal Facility
of the University of Pittsburgh in strict accordance with the
Institutional Animal Care and Use Committee of the
University of Pittsburgh guidelines.
RESULTS
Changes in cytokine mRNA levels over 120 days after
whole lung irradiation 
Our previous studies demonstrated that intratracheal
injection of manganese superoxide dismutase (MnSOD)
plasmid/liposome complex prior to whole lung irradiation
decreased radiation-induced organizing alveolitis/fibrosis in
C57BL/6J mice and improved survival [38,40]. The success
of radioprotective gene therapy was correlated with
detectable expression of transgene mRNA in alveolar type-two
cells and tracheobronchial cells of treated mice, and with an
elevated level of biochemically detectable MnSOD in
explanted lung tissue 24 hours after gene therapy and imme-
diately before irradiation. MnSOD plasmid/liposome gene
therapy groups, compared to LacZ gene therapy irradiated
mice or the irradiated control mice, demonstrated a
decrease in the irradiation-induced levels of endogenous
MnSOD in mouse lung, and also showed a decrease in
irradiation-induced mRNA levels for TGF-b, IL-1, and
TNF-a at early time points after irradiation [38,40]. 
A major question arising from our prior studies focused
on the role of cytokine elevation following irradiation on
the late effect of organizing alveolitis/fibrosis. Mice in our
previous studies were followed until the time of death, and
histopathology with quantitation of the percent of lung
containing organizing alveolitis was evaluated at death or
when mice were moribund. No information was available
from these first experiments on whether chronic elevation of
cytokine levels or delayed peak elevation of specific inflam-
matory or fibrosis-associated cytokine levels was correlated
with the severity of organizing alveolitis, nor could we
determine whether the single administration of MnSOD
plasmid/liposomes 24 hours prior to irradiation had altered
the late expression of cytokine mRNA levels in the lung.
In the present studies, 600 mice were divided into three
groups receiving daily administration of MnSOD plasmid/lipo-
some gene therapy, LacZ plasmid/liposome control transgene
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administration, or no plasmid/liposome injection, 24 hours
prior to 2000 cGy whole lung irradiation. The 2000 cGy dose
was chosen based on our previous studies and was higher than
the 1800 cGy or 1900 cGy dose [38]. This higher dose was
chosen to attempt to amplify cytokine mRNA changes and to
provide the optimum ability to correlate potential early irradi-
ation-induced histopathologic changes with cytokine mRNA
levels. For this large study, a subgroup of mice was followed
until death and seven other subgroups from each main group
were sacrificed at days 1, 4, 7, 14, 80, 100, or 120 after whole
lung irradiation. These groups of sacrificed animals were eval-
uated for levels of mRNA for IL-1, TGF-b (and isoforms
TGF- b1, TGF- b2 and TGF- b3), and TNF-a in whole
lung tissue immediately after explant and fragments of lung
from each of the five lobes were analyzed rigorously for
histopathologic evidence of organizing alveolitis according to
our published methods [38,40]. 
C57BL/6J mice were intratracheally injected with either
LacZ or MnSOD plasmid/liposome complex and irradiated
24 hours later, along with control mice, to 2000 cGy to the
pulmonary cavity. The mice were sacrificed at various time
points following irradiation or at time prior to death. RNA
was extracted from the lungs, which were excised and frozen
in liquid nitrogen. Slot blot analysis was used to quantitate
the expression of mRNA for IL-1 by probing the blots with
a p32-PCR fragment of IL-1, stripping the blot and probing
for actin. Expression was measured by densitometric meas-
urements of the x-ray film from the blots with the results
normalized by comparing IL-1 expression with actin and,
separately, with G3PDH expression. 
Lung specimens were analyzed for levels of mRNA for
IL-1, TNF- a, and each of three TGF-b isoforms from
subgroups of at least five mice at each time point. At least
five samples of lung were evaluated in each cytokine assay by
slot blot and the results normalized for each fragment of
lung to actin and G3PDH content in that fragment. The
results were presented as the mean and standard deviation
for each mouse and then mean and standard error for each
group of five mice. As shown in Fig. 1, irradiated control
mice as well as those receiving LacZ plasmid/liposome
Figure 1. Increased cytokine expression in the lung following 2000 cGy irradiation
Control C57BL/6J mice, as well as mice injected intratracheally with either LacZ plasmid/liposome complex or MnSOD plasmid/liposome complex 24 hours pre-
viously, were irradiated to a dose of 2000 cGy to the pulmonary cavity. At 0, 1, 4, 7, 14, 80, 100, or 120 days following irradiation or at the time of death, the
mice were sacrificed, and the lungs were removed and snap frozen in liquid nitrogen. RNA was isolated and slot blot analysis was performed. The blots were probed
with a p32-labeled PCR fragment for IL-1 (A), TNF-a (B), or TGF-b (C), and then stripped and reprobed with a p32-labeled PCR fragment of actin. The
RNA was quantitated spectrophotometrically and data reported as cytokine:actin ratios to normalize for RNA loading. There was an increase in IL-1 expression on
days 1 and 7 following irradiation (A). For TNF-a (B), there was an increase at 80 and 100 days after irradiation, but decreases at 120 days and at the time of
death. There was an initial increase in TGF-b (C) following irradiation, which returned to background levels by day 14. At 100 days, there was an increase in
TGF-b expression which continued to increase to 120 days and at the time of death. Cytokine levels for mice injected with the MnSOD plasmid/liposome complex
were compared to control mice using a Student t-test (significant differences with a p , 0.05 are indicated by an asterisk [*]).
demonstrated a significant increase in mRNA levels for IL-1,
detectable as early as 1 day after irradiation and significantly
elevated at 7 days after irradiation. IL-1 mRNA levels
decreased after day 7 and did not rise again significantly
over the 120-day observation period and were not elevated
at death. While there was no statistically significant difference
between IL-1 mRNA levels in the LacZ plasmid/liposome
group compared to irradiated controls, MnSOD plasmid/lipo-
some administration prior to irradiation significantly
decreased the irradiation-induced elevation of IL-1 mRNA
at days 4, 7, and 14 after irradiation (Fig. 1A). When the
data were normalized to G3PDH (Table 1), the irradiation-
induced increase was again detectable, and a significant
decrease in irradiation-induced upregulation of IL-1 in the
MnSOD plasmid/liposome group was detected at days 80
and 120 (Table 1). These results confirm and extend those of
our prior studies [38] and are consistent with the observation
that IL-1 is an acute phase inflammatory cytokine responding
to pulmonary damage resulting from infection, chemical
toxicity, or exposure to DNA damaging agents.
The results with mRNA levels for TNF-a at each of the
time points evaluated are shown in Fig. 1B. The expression of
TNF-a was determined by spectrophotometrical analysis of
X-ray films of the blots with the expression of the RNA
normalized by comparing to actin expression with the results
shown above as TNF-a:actin ratios. A Student t-test was used
to compare TNF-a expression in MnSOD plasmid/liposome
complex-injected mice with control mice and mice injected
with LacZ, and significant differences were detected at days 4,
7, and 14 (p , 0.05). Irradiated control mice demonstrated an
increase in TNF-a mRNA levels detectable at day 4 and
significantly increasing at days 80 and 100. Mice injected with
MnSOD plasmid/liposome complex prior to irradiation
showed significantly decreased TNF-a mRNA levels at days
4, 7, and 14 after irradiation. There was then a significant
decrease in TNF-a mRNA levels at 120 days and at the time
of death, compared to those levels detected at 80 and 100
days. These results were similar for the mice receiving LacZ
plasmid/liposome administration prior to irradiation. In the
mice receiving MnSOD plasmid/liposome gene therapy prior
to irradiation, there was a significant decrease in irradiation-
induced mRNA levels for TNF-a detectable at days 4, 7, and
14 after irradiation. 
When the data were normalized to G3PDH, we detected
persistently elevated levels of TNF-a mRNA after irradiation
out to day 120, and a significant decrease in TNF-a levels of
mRNA at 120 days in the MnSOD plasmid/liposome group
(Table 2). These results further confirm and extend our prior
Table 1. Expression of IL-1 mRNA in the lung following 
2000 cGy irradiation normalized to G3PDH
Days After 2000 cGy Irradiation
Group 0 80 100 120 Death
Control 0.341 6 0.037 0.329 6 0.026 0.848 6 0.227 1.201 6 0.341 0.361 6 0.050
LacZ 0.186 6 0.087 0.777 6 0.245 0.781 6 0.233 0.763 6 0.143 0.487 6 0.255
MnSOD 0.370 6 0.087 0.071 6 0.006* 0.620 6 0.155 0.221 6 0.089* 0.210 6 0.020
C57BL/6J mice were injected with either MnSOD or LacZ plasmid/liposome complex. Control mice, as well as mice injected with MnSOD or LacZ
plasmid/liposome complex were irradiated to the pulmonary cavity to 2000 cGy, 24 hours after injection with MnSOD or LacZ plasmid/liposome complex. The
mice were sacrificed on days 0, 80, 100, and 120 after irradiation, and the lungs removed and frozen in liquid nitrogen. RNA was extracted and slot blot analysis
performed to quantitate mRNA expression of IL-1 by probing with a p32-labeled PCR fragment for IL-1. The blots were stripped and reprobed with a p32-labeled
probe G3PDH. Expression was measured by densitometric measurements of the x-ray film from the blots with IL-1 expression normalized by comparison to
G3PDH expression. The above results are IL-1:G3PDH ratios. A Student t-test was used to compared IL-1 expression for MnSOD plasmid/liposome-injected
mice to the control irradiated mice with significant differences (p , 0.05) indicated by an asterisk (*). IL-1 expression was significantly decreased in mice injected
with MnSOD plasmid/liposome complex 80 and 120 days after irradiation. These differences were not detected when data was normalized to actin (Figure 1A).
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Table 2. Expression of TNF-a in the lung following 2000 cGy irradiation normalized to G3PDH
Days After 2000 cGy Irradiation
Group 0 80 100 120 Death
Control 5.912 6 0.5191 7.252 6 1.258 15.78 6 0.043 11.42 6 1.601 7.141 6 1.139
LacZ 4.286 6 1.030 19.15 6 2.784 18.86 6 2.249 6.750 6 0.798 11.24 6 3.322
MnSOD 5.647 6 1.437 12.72 6 1.683 12.84 6 1.610 5.176 6 0.988* 9.478 6 2.149
Control C57BL/6J mice, as well as mice which had been injected intratracheally 24 hrs previously, were irradiated to 2000 cGy to the pulmonary cavity.  Following
irradiation, the mice were sacrificed at days 0, 80, 100, 120 and time of death, and the lungs excised and frozen in liquid nitrogen.  RNA was extracted and slot
blot analysis was performed to determine the expression of TNF-a following irradiation.  The blots were probed with a p32-labeled PCR fragment of TNF-a , and
stripped and probed with a p32 probe for G3PDH.  The expression of TNF-a was determined by spectrophotometric analysis of x-ray film of the blots with the
expression normalized by comparing G3PDH expression.  Results are shown as TNF-a :G3PDH ratios.  A Student t-test was used to compare TNF-a expression
in MnSOD plasmid/liposome complex-injected mice with control mice and mice injected with LacZ plasmid/liposome complex with significant differences (p<0.05)
indicated by an asterisk (*).  Mice injected with MnSOD plasmid/liposome complexes showed significantly lower levels of TNF-a mRNA at 120 days after irradiation,
compared to the control irradiated mice.  The effect of MnSOD gene therapy on decrease in TNF-a at 120 days was not detected when the data was normalized to
actin (Figure 1B).
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data on the effects of MnSOD plasmid/liposome gene therapy
on cytokine mRNA induction in the lung at these earlier
time points [38]. Mice in the MnSOD plasmid/liposome
group demonstrated a late elevation in TNF-a mRNA at
days 80 and 100, and a decrease at day 120 and at death.
There was a significant effect of MnSOD plasmid/liposome
gene therapy with respect to lowering postirradiation TNF-a
levels at earlier time points, and the late sustained elevation
in TNF-a and drop in levels prior to the time of death was
also detectably decreased at day 120 by this schedule of
MnSOD plasmid/liposome delivery.
The results of detection of mRNA levels for total TGF-b
and each of three isoforms of TGF-b in the lungs of mice in
each group are shown in Fig. 1C and in Tables 3–6. The
expression of each TGF-b isoform was normalized by com-
paring it to G3PDH (Tables 4–6). The results with total
TGF-b are presented as TGF-b:actin ratios (Fig. 1C) and
TGF-b:G3PDH ratios (Table 3). A Student t-test was used
to compare the control mice and mice injected with LacZ
plasmid/liposome complex with mice injected with MnSOD
plasmid/liposome. Control irradiated mice demonstrated a
significant increase compared to preirradiation levels in
TGF-b at 1 day after irradiation followed by a decrease to
levels similar to that prior to irradiation. A late increase in
total TGF-b levels at 120 days and at the time of death was
detected (Fig. 1C, Table 3). The late peak increase in elevation
of TGF-b was clearly different in its pattern from that of
the decrease prior to death, compared to TNF-a levels
(Fig. 1B). Mice injected with MnSOD plasmid/liposome
complex showed significantly decreased (p , 0.05) levels of
total TGF-b mRNA at days 7, 14, 100, and 120 after irradi-
ation (late significant differences with a p , 0.05 are indicat-
ed by an asterisk [*]) (Fig. 1C; Table 3). The results of meas-
urement of mRNA levels for each TGF-ß isoform (Tables
4–6) were similar in the groups receiving irradiation alone
or LacZ plasmid/liposome administration prior to irradia-
tion with respect to the late elevation of TGF-ß1 at 100
days, and TGF-ß2 at day 120 and at the time of death. In
contrast, mice receiving MnSOD plasmid/liposome gene
therapy demonstrated a significant decrease in total TGF-b
levels (Fig. 1C, Table 3) and TGF-b1 levels (Table 4), com-
pared to control irradiated or LacZ plasmid/liposome-treated
animals at days 7 and 14, and at the late elevation points of
100 days for TGF-b1, and 120 days for TGF-b2 (Tables 4
and 5, respectively). Results with measurement of TGF-b2
and TGF-b3 normalized to G3PDH are shown in Tables 5
and 6, respectively. There was no detectable change in
TGF-b3 levels at any time point.
While there was a significant decrease in TGF-b mRNA
levels at 120 days in the MnSOD plasmid/liposome-treated
group, the levels of mRNA in lung tissue at the time of death
were not significantly lower than those in the other groups.
While mRNA levels within each group at each time point had
large standard error bars for some data points (example: day 0
for TGF-b irradiated control group), the patterns of difference
in mRNA levels normalized to actin or G3PDH clearly
Table 4. Expression of TGF-b1 mRNA in the lung following 2000 cGy irradiation normalized to G3PDH
Days After 2000 cGy Irradiation
Group 0 80 100 120 Death
Control 0.065 6 0.027 0.001 6 0.001 0.163 6 0.053 0.015 6 0.009 0.021 6 0.011
LacZ 0.006 6 0.004 0.025 6 0.012 0.094 6 0.045 0.016 6 0.006 0.047 6 0.019
MnSOD 0.020 6 0.001 0.010 6 0.004 0.059 6 0.008* 0.020 6 0.004 0.012 6 0.004
C57BL/6J mice were injected intratracheally with either MnSOD or LacZ plasmid/liposome complex. Twenty-four hours later, control and injected mice were
irradiated to 2000 cGy to the pulmonary cavity. The mice were sacrificed on days 0, 80, 100, and 120 following irradiation, or at the time of death, and the lungs
excised and snap frozen in liquid nitrogen. The RNA was extracted and analyzed for expression of TGF-b1 mRNA by slot blot analysis. The blots were probed
with a p32-labeled fragment of the rat TGF-b1 gene, which recognizes the murine TGF-b1 mRNA. The blots were stripped and reprobed with a p32-labeled
PCR fragment for G3PDH. The expression of TGF-b1 was normalized to G3PDH expression with the results shown as TGF-b1:G3PDH ratios. A Student
t-test was used to compare the expression of MnSOD plasmid/liposome complex-injected mice to that of irradiated control mice (significant differences with a p ,
0.05 are indicated by an asterisk [*]). Expression of TGF-b1 increased 100 days after irradiation and then decreased by 120 days. MnSOD plasmid/liposome-injected
mice had a significantly lower expression of TGF-b1 at 100 days, compared to the control irradiated mice.
Table 3. Expression of TGF-b in the lung following 2000 cGy irradiation normalized to G3PDH
Days After 2000 cGy Irradiation
Group 0 80 100 120 Death
Control 0.105 6 0.011 0.434 6 0.254 0.474 6 0.175 8.305 6 1.464 5.813 6 1.355
LacZ 0.202 6 0.077 0.119 6 0.049 0.827 6 0.242 4.804 6 0.844 7.641 6 3.044
MnSOD 0.135 6 0.017 0.205 6 0.083 0.063 6 0.025* 2.305 6 0.266* 3.913 6 1.056
Control C57BL/6J mice, as well as mice intratracheally injected 24 hours previously with either MnSOD plasmid/liposome complex or LacZ plasmid/liposome,
were irradiated to 2000 cGy. The mice were sacrificed at 0, 80, 100, or 120 days after irradiation or at the time of death, and the lungs excised and snap frozen
in liquid nitrogen. RNA was extracted and expression of mRNA for TGF-b was measured using slot blot analysis. The blots were probed with a p32-PCR frag-
ment for TGF-b, and stripped and probed with a p32-PCR fragment for G3PDH. The expression of TGF-b was normalized by comparing G3PDH with the
results shown as TGF-b:G3PDH ratios. A Student t-test was used to compare the control mice and mice injected with LacZ plasmid/liposome complex with the
MnSOD plasmid/liposome-injected mice (significant differences with a p , 0.05 indicated by an asterisk [*]). Mice injected with MnSOD plasmid/liposome com-
plex showed significantly decreased TGF-b mRNA at days 100 and 120 after irradiation. 
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demonstrated a difference in the kinetics of appearance of IL-1,
TNF-a and TGF-b isoform mRNA levels, which were uniform
between groups and uniform in peak elevation at specific time
points. These data establish that pulmonary IL-1 mRNA levels
increased initially after total lung irradiation and fell to lower
levels until the time of death. They also demonstrate that a
progressive increase in TNF-a mRNA levels after irradiation
was associated with a decrease around the time that a second
peak elevation of TGF-b1 and TGF-b2 isoform levels was
detected in all groups.
Histopathologic changes associated with organizing
alveolitis/fibrosis are detected after 120 days
following total lung irradiation
Rigorous histopathologic evaluation of all five lobes
from each lung of each individual mouse within each subgroup
sacrificed at days 80, 100, and 120 were compared to the
results of histopathologic evaluation at the time of death.
Our previous studies of total lung irradiation in the
C57BL/6J mouse have demonstrated that there is no reliable
physiologic measurement prior to morbidity and death in
this strain, suggesting the histopathologic changes occurred
rapidly before the time of death [38]. To determine whether
detectable changes in histopathology were present at earlier
time points, each subgroup was carefully compared with
each other group and with representatives from its own
group at different time points. 
As shown in Fig. 2, there was no detectable increase in
the percent of lung containing histopathologically detectable
organizing alveolitis at 80 days or 100 days after total lung
irradiation compared to control levels in the present study
(data not shown) or studies published by us previously [38].
In contrast, at 120 days, there was an increase in percent
alveolitis in the MnSOD plasmid/liposome gene therapy
Figure 2. Percent alveolitis in the lungs following irradiation
Control C57BL/6J mice, as well as mice injected intratracheally with either LacZ plasmid/liposome complex or MnSOD plasmid/liposome complex 24 hours
previously, were irradiated to 2000 cGy to the pulmonary cavity. The mice were sacrificed at 80, 100, or 120 days after irradiation or at the time of death, and
the lungs excised, frozen in OCT, sectioned and H&E stained. The percent alveolitis was determined using the Optimus Image Analysis System. No significant
increase in alveolitis was detected before the time of death.
Table 5. Expression of TGF-ß2 mRNA in the lung following 2000 cGy irradiation normalized to G3PDH
Days After 2000 cGy Irradiation
Group 0 80 100 120 Death
Control 0.081 6 0.011 0.064 6 0.026 0.067 6 0.034 0.273 6 0.026 0.277 6 0.533
LacZ 0.050 6 0.013 0.109 6 0.032 0.039 6 0.011 0.182 6 0.026 0.243 6 0.042
MnSOD 0.082 6 0.013 0.067 6 0.006 0.023 6 0.003 0.108 6 0.027* 0.502 6 0.159
Control C57BL/6J mice, as well as mice that had been intratracheally injected with either MnSOD or LacZ plasmid/liposome complex 24 hrs previously, were
irradiated to 2000 cGy to the pulmonary cavity.  At  0, 80, 100, 120 days after irradiation, as well as at the time of death, the mice were sacrificed with the lungs
excised and frozen in liquid nitrogen.  RNA was extracted and slot blot analysis was performed to determine the expression of TGF-ß2 mRNA.  The blots were
probed with a p32-labeled fragment of the murine TGF-ß2 gene, and stripped and probed with a p32-labeled G3PDH PCR fragment.  The expression of TGF-ß2
mRNA was determined by spectrophotometrical analysis of x-ray films with the expression normalized by comparison to the expression of G3PDH, with results
presented as TGF-ß2:G3PDH ratios.  A Student t-test was used to compare the expression of TGF-ß2 expression of MnSOD plasmid/liposome complex-injected
mice to that of the control mice [significant differences of p<0.05 are indicated by an asterisk (*)].  TGF-ß2 expression increased at 120 days after irradiation and
remained elevated at the time of death.  Mice injected with MnSOD plasmid/liposome complex had a significantly lower expression of TGF-ß2 at 120 days than
the control or LacZ plasmid/liposome complex-injected mice.
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group and a significant increase in all three groups at death
(Fig. 2, Table 7). As shown in Fig. 3, there was a significant
increase in survival in the MnSOD plasmid/liposome gene
therapy group, compared to the 2000 cGy irradiated control
or LacZ plasmid/liposome complex-treated groups. These
results confirm and extend those of our prior studies using
lower single-fraction doses of irradiation [38]. The earlier
death of mice in the control irradiated group between days
100 and 150 may be considered when analyzing the data in
Table 1 showing percent organizing alveolitis. The percent
alveolitis of 5.800 6 0% in the control group reflected
unprotected mice who died significantly earlier than
those in the MnSOD plasmid/liposome group or the LacZ
plasmid/liposome group, even though the group composite
number for percent alveolitis appeared to be higher in the
plasmid/liposome-treated groups.
These results establish that the appearance of organizing
alveolitis correlated with the second peak increase in mRNA
levels for specific isoforms of TGF-b1 and TGF-b2. The
data further indicate that there was no detectable appearance
of histopathologic changes associated with organizing alveolitis
or fibrosis at 100 days, and in two of the groups at 120 days
(Table 7).
DISCUSSION
Pulmonary toxicity from TBI remains a major complication
in the preparative regimens for bone marrow transplantation
[1–7,10–12,14–15]. The pathophysiology of radiation pneu-
monitis and late radiation fibrosis are largely unknown, but the
sequelae of each presentation have led to speculation as to the
etiology of the causes of toxicity in TBI patients. Increased
levels of cytokine mRNA and plasma protein levels for IL-1,
TNF-a, and TGF-b have been associated with total lung
irradiation and have been suggested as contributing to the
radiation pneumonitis seen in TBI patients [29,31,34,42,51].
Elevated cytokine levels producing inflammatory cell reactions
in the lung have been suggested as etiologic agents in pul-
monary toxicity [10]. Opportunistic infection resulting from
the immunosuppression of TBI and/or elevated cytokine levels
has also been suggested [10,28,38,40]. Finally, pulmonary
vascular damage and the TBI effect of upregulation of vascular
adhesion molecules has been suggested as a potential etiologic
agents in radiation pneumonitis [34,52]. 
Lung shielding using transmission blocks and fraction-
ated radiotherapy have significantly decreased the acute
toxicity of whole body irradiation with respect to radiation
pneumonitis [8,18,22,27–28]. However, the worrisome
increase in relapse of myelodysplastic disease in patients
with lung shielding [8] suggests that protection of bone
marrow in ribs andvertebral bodies by the lead blocks may
be an undesirable outcome of this method of lung protec-
tion. Pharmacologic approaches to lung protection have
been attempted utilizing agents that have worked in vitro or
Figure 3. Increased survival of MnSOD plasmid/liposome
complex-injected mice irradiated to 2000 cGy
C57BL/6J mice were injected intratracheally with MnSOD or LacZ
plasmid/liposome complexes. The injected mice, as well as control mice were
irradiated to 2000 cGy to the pulmonary cavity 24 hours later and followed
for survival. The mice injected with MnSOD plasmid/liposome complex had a
significantly increased survival compared to the control and LacZ plasmid/lipo-
some complex-injected mice (p 5 0.003 and 0.006, respectively).
Table 6. Expression of TGF-b3 in the lung following 2000 cGy irradiation normalized to G3PDH
Days After 2000 cGy Irradiation
Group 0 80 100 120 Death
Control 0.04260.004 0.04460.006 0.01760.007 0.03160.011 0.03360.003
LacZ 0.05460.030 0.05360.013 0.04560.013 0.05860.012 0.05860.020
MnSOD 0.02460.005 0.04860.009 0.01160.005 0.01460.003 0.02860.016
Control C57BL/6J mice, as well as mice which had been injected 24 hrs previously with either MnSOD or LacZ plasmid/liposome complex, were irradiated to
2000 cGy to the pulmonary cavity. On days 0, 80, 100, and 120 after irradiation, as well as at the time of death, the mice were sacrificed and the lungs excised
and frozen in liquid nitrogen. The RNA was extracted and analyzed for the expression of the TGF-b3 isoform using slot blot analysis. The blots were probed with
a p32-labeled fragment of the murine TGF-b3 gene, and stripped and reprobed with a p32-labeled PCR fragment of the G3PDH gene. Expression of TGF-b3
was determined by spectrophotometrical analysis of X-ray films of the blots with the expression normalized by comparison of the expression of G3PDH, with results
presented as TGF-b3:G3PDH ratios. A Student t-test was used to compare the expression of TGF-b3 in the MnSOD plasmid/liposome complex-injected mice to
that of the control irradiated mice. There was no significant increase in expression of TGF-b3 at any time following irradiation. There also was no change in
expression of TGF-b3 in any of the different groups of mice following 2000 cGy irradiation. 
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in the oral cavity with limited success, perhaps due to
unavailability of the agents to the critical pulmonary cells or
to their nuclei [53–54].
The mouse model of total lung irradiation is not an ideal
one for studying acute radiation pneumonitis in humans
because the doses which produce an acute pulmonary effect
are beyond those associated with lethality from esophagitis at
30 days [30]. In other studies, we have demonstrated significant
protection of the mouse esophagus from irradiation-induced
lethal esophagitis by MnSOD plasmid/liposome gene therapy,
and this method of promoting survival of mice to doses
above 3000 cGy whole lung irradiation may provide a mech-
anism with which to study cytokine levels in the lung following
whole thorax irradiation under conditions where animals will
not die at 30 days due to esophagitis. However, in the current
analogous system to whole lung irradiation of TBI, doses
between 1800 cGy and 2000 cGy in the C57BL/6J model
appear to be ideally suited for studying cytokine levels associated
with the late lung irradiation.
While mice in the present 2000 cGy irradiated control
group did not die of radiation pneumonitis, these mice did
present an effective model for study of the cytokine mRNA
levels associated with late radiation fibrosis/organizing alveoli-
tis. The present results established that there was a slow
increase in detectable mRNA levels for TNF-a out to 100
days following total lung irradiation, followed by a drop to
control pre-radiation levels. The different survival rates of
control irradiated non-MnSOD plasmid/liposome-treated
mice in the present versus past studies reflect the use of differ-
ent animal care facilities [38] and C57BL/6J mice from differ-
ent breeding stocks. In contrast, a late peak elevation in
mRNA levels for specific isoforms of TGF-b was detected
between 100 and 120 days, and was significantly elevated at
the time of death. These results strongly suggest that TGF-b
mRNA levels and protein production in the lung are associat-
ed with the late and death-related lesion of organizing alve-
olitis/fibrosis. 
We did not measure actual cytokine protein levels in the
lung, and do not know which cells of the pulmonary parenchyma
are involved in the increased production of protein which was
associated with elevated mRNA levels and serum protein levels
[38]. Studies in progress with bronchoalveolar lavage to isolate
pulmonary macrophages should allow us to determine if these
and other inflammatory cells are involved in the irradiation-
induced upregulation of cytokine message levels and protection
by MnSOD plasmid/liposome therapy.
It is not known why the late elevation of specific TGF-b
isoforms is associated with the histopathologic lesion of
fibrosis, or why the increased level of TGF-b1 initially at
days 4–14 does not also rapidly induce fibrosis early after
irradiation. It is known that TGF-b has many different and
pleotrophic functions in the developing embryo and in the
adult [51]. Since our assay measured total levels of TGF-b
and only subgroups of TGF-b1, TGF-b2, TGF-b3 [56], it
is possible that the late peak elevation of TGF-b2 may
represent one of several molecular species different from
that detected in the earlier time points.
The presence of elevated levels of one cytokine in the
absence of elevated levels of other cytokines may produce a
very different response compared to elevation uniformly of
multiple cytokine levels. It is possible that in the 120-day
post irradiation lung, the elevated levels of specific TGF-b
isoforms in the absence of associated elevated IL-1, TNF-a
(or other cytokine levels which we did not study) may produce
the fibrosis-inducing effect. It is also possible that the levels
of some TGF-b isoform mRNAs detected after 100 days in
the irradiated lung may reflect a damage response from
slowly proliferating cells within the lung which required 120
days for cellular turnover and delayed apoptosis. Histopatho-
logic and histomorphometric studies using in situ nested
RT-PCR assays will be required to detect which cells in the
120-day post irradiation lung are responding with the
increased levels of TGF-b2 mRNA.
The complication of radiation damage from TBI
remains a major obstacle to successful attempts to
improve the preparatory regimen for allogeneic bone
marrow transplantation. It is an obstacle that must be
overcome and such efforts must take into account the need
to deliver a full dose to rib, clavicle, scapula, vertebral
body, and sternal bone marrow, where residual leukemia
lymphoma cells may reside [8]. Furthermore, successful
strategies for protection of the lung should not protect
lymph nodes in the mediastinum or in the pulmonary
parenchyma, which also may harbor malignant cells. A
strategy of radioprotective gene therapy using direct
intrapulmonary delivery of MnSOD plasmid/liposome
radioprotective genes must include a more complete
understanding of the molecular mechanism of protection.
The present studies add insight into the nature of the
duration of protection, but more importantly into the
profile of cytokine mRNA expression during the induc-
tion of radiation damage. 
Table 7. Percent alveolitis following 2000 cGy to the mouse lung
Days After 2000 cGy Irradiation
Group 80 100 120 Death
Control 0.077 6 0.1 0.041 6 0.04 0.206 6 0.2 5.800 6 2.0*
LacZ 0.320 6 0.2 0.359 6 0.2 0.194 6 0.1 7.681 6 1.6*
MnSOD 0.133 6 0.1 0.20 6 0.1 0.593 6 0.3 6.654 6 3.5*
Control C57BL/6J mice, as well as mice which had been injected 24 hours previously with either MnSOD or LacZ plasmid/liposome complex, were irradiated to
2000 cGy to the pulmonary cavity. On days 80, 100, and 120 after irradiation or at the time of death, the mice were sacrificed; and the were lungs excised, frozen
in OCT, sectioned and H&E-stained with the percent alveolitis calculated using an Optimus Image Analysis System [31]. No alveolitis was detected before the
time of death. There was no significant difference in the percent of alveolitis among the three groups of mice; however, all showed a significant increase in alveolitis
at death, compared to values at earlier time points within each group (p , 0.001). 
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